Drug Trial Radar · NCT01560637
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Last checked: Nov 19, 2026Latest source record: Jun 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
471
Actual
Start
Sep 11, 2013
Primary completion
Aug 12, 2021
Study completion Aug 12, 2021
Sponsor
- Lead sponsor
- United TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 22, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have completed the TDE-PH-310 study. The purpose of this study is to assess the long-term safety of UT-15C and to assess the effects of long-term treatment with UT-15C on exercise capacity.
Conditions
- Pulmonary Arterial Hypertension
Interventions
UT-15C (treprostinil diolamine)Drug
UT-15C extended release oral tablet three times daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse EventsTime frame: Participants will be followed every 12 weeks, at minimum, until they discontinue the study or the study is discontinued by the sponsor or for a period up to 2.5 years
Locations
153 sites in 23 countries. Site status is shown where the registry gives one.
Arizona Pulmonary Specialists, Ltd.
Phoenix, Arizona
University of Arizona
Tucson, Arizona
University of California, San Francisco-Fresno
Fresno, California
Cedars-Sinai Medical Center
Los Angeles, California
University of California-Davis Medical Group, Advanced Lung Disease/Transplant Program
Sacramento, California
David Geffen School of Medicine
Torrance, California
University of Colorado Hospital
Aurora, Colorado
University of Florida
Gainesville, Florida
University of Florida College of Medicine Jacksonville- Division of Pulmonary & Critical Medicine
Jacksonville, Florida
Cleveland Clinic Florida
Weston, Florida
Emory University Hospital
Atlanta, Georgia
Augusta University
Augusta, Georgia
Piedmont - Georgia Lung Associates
Austell, Georgia
HeartCare Midwest
Peoria, Illinois
Indiana University Hospital
Carmel, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Kentuckiana Pulmonary Associates
Louisville, Kentucky
University of Maryland
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
Beaumont Health
Troy, Michigan
Nebraska Medical Center
Omaha, Nebraska
Newark Beth Israel Medical Center
Newark, New Jersey
University of Rochester
Rochester, New York
Asheville Cardiology Associates
Asheville, North Carolina
University of Cincinnati
Cincinnati, Ohio
University Hospital
Cleveland, Ohio
Ohio State University
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
Legacy Research Institute
Portland, Oregon
Perelman Center for Advanced Medicine, University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center - Presbyterian Cardiovascular Institute
Pittsburgh, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
The University of Texas Health Science Center at Houston
Houston, Texas
Sentara Cardiovascular Research Institute
Norfolk, Virginia
Virginia Commonwealth University
Richmond, Virginia
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin
Sanatorio de la Trinidad Mitre
Buenos Aires, Argentina
Hospital Dr. José María Cullen
Santa Fe, Argentina
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.